XenoPort Reports Feedback from FDA on XP23829

By: Benzinga
XenoPort (NASDAQ: XNPT ) today reported an update on XP23289 development, including feedback from the U.S. Food and Drug Administration (FDA) on the potential development plans, and XenoPort's progress on
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.